Leerink Partnrs Analysts Lower Earnings Estimates for MREO

Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) – Analysts at Leerink Partnrs dropped their Q4 2025 earnings per share (EPS) estimates for Mereo BioPharma Group in a research note issued to investors on Monday, November 10th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of $0.04 for the quarter, down from their prior estimate of $0.05. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

A number of other brokerages have also weighed in on MREO. JPMorgan Chase & Co. raised their price target on shares of Mereo BioPharma Group from $7.00 to $8.00 and gave the company an “overweight” rating in a report on Monday, August 25th. Wall Street Zen raised Mereo BioPharma Group from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mereo BioPharma Group in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Mereo BioPharma Group from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, Mereo BioPharma Group presently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

Mereo BioPharma Group Trading Up 5.6%

Shares of NASDAQ MREO opened at $1.87 on Wednesday. Mereo BioPharma Group has a 1-year low of $1.47 and a 1-year high of $4.29. The company has a 50-day moving average of $1.91 and a two-hundred day moving average of $2.10. The company has a market cap of $297.33 million, a PE ratio of -31.17 and a beta of 0.41.

Mereo BioPharma Group (NASDAQ:MREO) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.01) EPS for the quarter. The business had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $3.70 million.

Hedge Funds Weigh In On Mereo BioPharma Group

A number of large investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. grew its stake in shares of Mereo BioPharma Group by 53.4% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 7,819,863 shares of the company’s stock worth $17,595,000 after acquiring an additional 2,722,084 shares in the last quarter. Aberdeen Group plc boosted its holdings in Mereo BioPharma Group by 82.9% during the third quarter. Aberdeen Group plc now owns 5,538,699 shares of the company’s stock worth $11,410,000 after purchasing an additional 2,509,827 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Mereo BioPharma Group by 62.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,569,100 shares of the company’s stock valued at $3,530,000 after purchasing an additional 604,200 shares in the last quarter. Monaco Asset Management SAM increased its stake in Mereo BioPharma Group by 139.5% in the 3rd quarter. Monaco Asset Management SAM now owns 945,915 shares of the company’s stock valued at $1,949,000 after buying an additional 550,915 shares during the last quarter. Finally, Atle Fund Management AB lifted its position in Mereo BioPharma Group by 96.1% during the 2nd quarter. Atle Fund Management AB now owns 764,901 shares of the company’s stock worth $2,073,000 after buying an additional 374,901 shares in the last quarter. Institutional investors and hedge funds own 62.83% of the company’s stock.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.